Preferred Label : Anbenitamab;
NCIt synonyms : HER2 Bispecific Antibody KN026; Anti-HER2 Heterodimeric Antibody KN026; Anti-HER-2 Bispecific Antibody KN026;
NCIt definition : An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from
trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular
dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor
epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating
and antineoplastic activities. Upon administration, anbenitamab simultaneously targets
and binds to two separate, non-overlapping epitopes of HER-2, thereby inhibiting HER-2
heterodimerization and prevents the activation of HER-2 signaling pathways. By binding
to HER-2, KN026 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against
tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits
tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed
on a variety of tumor cell types, plays an important role in proliferation, differentiation
and survival.;
UNII : RHS90QRF9E;
CAS number : 2367012-88-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2367012-88-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : KN-026; KN 026;
NCI Metathesaurus CUI : CL971091;
Origin ID : C162577;
UMLS CUI : C5554566;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
